Cytokinetics targets >50% MYQORZO new-to-brand share by end of 2026 while planning nHCM sNDA in Q4 (NASDAQ:CYTK)
· seekingalpha.com
Cytokinetics (CYTK) Q2 2026 earnings call: MYQORZO launch momentum, revenue beat, raised spend guide, and Q4 aficamten sNDA plans—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...